Nexalis Therapeutics LimitedASX: NX1

First eligible participant screened - phase 1 IRX-616a study

Mar 4, 2026 at 5:47 AM UTC · Issued by Nexalis Therapeutics Limited

Nexalis Therapeutics Limited has released a press release.

View Attachment

Earlier from Nexalis Therapeutics

All Nexalis Therapeutics news releases